Clinical Trials Logo

Clinical Trial Summary

Hyperphosphatemia and elevated cardiac biomarkers are two key characteristics of patients in end stage renal diseases(ESRD),however the majority of whom are in the absence of acute coronary syndrome(ACS). And it is still unclear why cardiac biomarkers would increase in those patients. We hypothesized that excessive phosphorus is account for that phenomenon.To confirm that hypothesis,we used one phosphorus binder to reduce phosphorus absorption in hemodialysis patients for some time and observed the change of cardiac biomarkers of those patients.


Clinical Trial Description

Cardiovascular disease is one of the leading causes of morbidity and mortality in patient with chronic kidney disease(CKD), accounting for more than 50% of all deaths.When myocardial cells get injured, cardiac biomarkers will be released into the circulation. Elevated cardiac biomarkers have been observed in patients with various degrees of renal failure. However, the majority of those CKD patients are in the absence of acute coronary syndrome. So far, it is still unclear the mechanisms of the increased biomarkers in CKD patients. Meanwhile, hyperphosphatemia is one of the major features of CKD, particularly of end stage renal disease(ESRD). Lots of evidences have shown that high levels of serum phosphorus and an elevation of the serum calcium × phosphorus product can lead to cardiovascular calcifications and subsequent cardiovascular morbidity and mortality in patients with CKD.it is tempting to hypothesize that hyperphosphatemia may be responsible for the rise of cardiac biomarkers in CKD patients.So we use one phosphate binder to reduce phosphorus absorption in hemodialysis patients for one year and observe the change of cardiac biomarkers of those patients. ;


Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01781156
Study type Observational
Source Shanghai 10th People's Hospital
Contact Ai Peng, Ph.D,M.D
Phone 86-021-66302524
Email pengai@hotmail.com
Status Recruiting
Phase N/A
Start date August 2012
Completion date June 2018

See also
  Status Clinical Trial Phase
Completed NCT01766882 - Volume,Sodium and Blood Pressure Management in HD N/A
Completed NCT01037595 - Effect of Turmeric on Pruritus in Hemodialysis Patients Phase 0
Completed NCT02686398 - Immunogenicity of a Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Undergoing Hemodialysis Phase 4
Active, not recruiting NCT04376567 - Outcomes for One-stage and Two-stage Brachial Basilic Arteriovenous Fistulas N/A
Completed NCT01990118 - Gengraf Conversion Study in Stable Renal Allograft Transplant Recipients Phase 4
Recruiting NCT01704313 - A Trial of Interrupted vs Continuous Suturing Techniques for Radiocephalic Fistulae N/A
Not yet recruiting NCT06389617 - Different Doses of Intravenous Administered Dexamethasone Effecting Brachial Plexus Supraclavicular Block N/A
Completed NCT01004627 - A Study of Routine Versus Selective Use of Ultrasound Scanning Prior to Haemodialysis Fistula Surgery N/A
Recruiting NCT02895425 - Registry for End Stage Renal Failure N/A
Not yet recruiting NCT02341547 - Effectiveness of a Biosimilar Epoetin Alfa in Stable 'End Stage Renal Failure' N/A
Completed NCT01834755 - Physical and Psychological Profiles Associated With Patient's Preference for ESRD Treatment N/A
Completed NCT01101217 - Effect of Zinc Suplementation on Serum Hemosystein Level in Hemodialysis Patients N/A
Completed NCT01996930 - Steroid Impregnated Tape in the Treatment of Over-granulating Peritoneal Dialysis Exit Sites Phase 3
Not yet recruiting NCT01704339 - Qutenza for Critical Ischaemia in End Stage Renal Failure Phase 4
Completed NCT01906840 - Role of Turmeric on Oxidative Modulation in ESRD Patients Phase 1/Phase 2
Not yet recruiting NCT06378931 - Quality of Life Change in Patients Undergoing Parathyroidectomy With End-stage Renal Failure